CRC Research Update — August 19, 2026
Today's colorectal cancer research highlights
rectal
A collection of 44 issues
CRC Research Update — August 10, 2026
Today's colorectal cancer research highlights
Intensified Total Neoadjuvant Therapy Improves Survival in High-Risk Rectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Intensified Total Neoadjuvant Therapy Improves Survival in High-Risk Rectal Cancer
A Chinese phase III trial of 458 patients with high-risk locally advanced rectal cancer found that integrating long-course radiotherapy with uninterrupted capecitabine and oxaliplatin chemotherapy (doublet-LC TNT) achieved 3-year disease-free survival of
Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery
Skip to content
The CRC Digest
▸ TREATMENT
Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery
A multicenter study of 3,385 rectal cancer patients aimed to compare short-term recovery, 6-month functional outcomes, and long-term survival among natural orifice specimen extraction surgery, laparoscopic surgery, and open surgery. (Diseases of
KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer
A meta-analysis investigated whether different KRAS mutation subtypes affect pathological complete response rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. The study examined KRAS mutations within and outside exon 2.
AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapy
Skip to content
The CRC Digest
◇ RESEARCH
AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapy
A post-hoc analysis of the phase III ARISTOTLE trial found that higher tumor cell density predicted improved survival in locally advanced rectal cancer patients receiving irinotecan-intensified neoadjuvant chemoradiotherapy; researchers developed a free
CRC Research Update — August 03, 2026
Today's colorectal cancer research highlights
Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer
A multicenter, randomized phase III trial evaluated total neoadjuvant therapy with long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology)
This content is
Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer
A phase Ib study to assess the safety of neoadjuvant trifluridine/tipiracil combined with concurrent radiation in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer)
This content
Anastomotic leakage shows minimal long-term impact on quality of life after rectal cancer surgery
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Anastomotic leakage shows minimal long-term impact on quality of life after rectal cancer surgery
A Swedish population-based study found that while anastomotic leakage after anterior resection is associated with long-term bowel dysfunction, its impact on health-related quality of life 3 years